| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:seeAlso
| |
| Description
| - Primary cutaneous posttransplant lymphoproliferative disorders (PTLD) are rare. This retrospective, multicenter study of 35 cases aimed to better describe this entity. Cases were (re)-classified according to the WHO-EORTC or the WHO 2008 classifications of lymphomas. Median interval between first transplantation and diagnosis was 85 months. Fifty-seven percent of patients had a kidney transplant. Twenty-four cases (68,6%) were classified as primary cutaneous T cell lymphoma (CTCL) and 11 (31,4%) as primary cutaneous B cell PTLD. Mycosis fungoides (MF) was the most common (50%) CTCL subtype. Ten (90,9%) cutaneous B cell PTLD cases were classified as EBV-associated B cell lymphoproliferations (including one plasmablastic lymphoma and one lymphomatoid granulomatosis) and one as diffuse large B cell lymphoma, other, that was EBV-negative. Sixteen (45,7%) patients died after a median follow-up of 19.5 months (11 [68,8%] with CTCL [6 of whom had CD30+ lymphoproliferative disorders (LPD)] and 5 [31,2%] with cutaneous B cell PTLD. Median survival times for all patients, CTCL and cutaneous B cell PTLD subgroups were 93, 93 and 112 months, respectively. Survival rates for MF were higher than those for CD30+ LPD. The spectrum of primary CTCL in organ transplant recipients (OTR) is similar to that in the general population. The prognosis of posttransplant primary cutaneous CD30+ LPD is worse than postrtransplant MF and than its counterpart in the immunocompetent population. EBV-associated cutaneous B cell LPD predominates in OTR.
- Primary cutaneous posttransplant lymphoproliferative disorders (PTLD) are rare. This retrospective, multicenter study of 35 cases aimed to better describe this entity. Cases were (re)-classified according to the WHO-EORTC or the WHO 2008 classifications of lymphomas. Median interval between first transplantation and diagnosis was 85 months. Fifty-seven percent of patients had a kidney transplant. Twenty-four cases (68,6%) were classified as primary cutaneous T cell lymphoma (CTCL) and 11 (31,4%) as primary cutaneous B cell PTLD. Mycosis fungoides (MF) was the most common (50%) CTCL subtype. Ten (90,9%) cutaneous B cell PTLD cases were classified as EBV-associated B cell lymphoproliferations (including one plasmablastic lymphoma and one lymphomatoid granulomatosis) and one as diffuse large B cell lymphoma, other, that was EBV-negative. Sixteen (45,7%) patients died after a median follow-up of 19.5 months (11 [68,8%] with CTCL [6 of whom had CD30+ lymphoproliferative disorders (LPD)] and 5 [31,2%] with cutaneous B cell PTLD. Median survival times for all patients, CTCL and cutaneous B cell PTLD subgroups were 93, 93 and 112 months, respectively. Survival rates for MF were higher than those for CD30+ LPD. The spectrum of primary CTCL in organ transplant recipients (OTR) is similar to that in the general population. The prognosis of posttransplant primary cutaneous CD30+ LPD is worse than postrtransplant MF and than its counterpart in the immunocompetent population. EBV-associated cutaneous B cell LPD predominates in OTR. (en)
|
| Title
| - Primary Cutaneous Posttransplant Lymphoproliferative Disorders in Solid Organ Tranpsplant Recipients: A Multicenter European Case Series
- Primary Cutaneous Posttransplant Lymphoproliferative Disorders in Solid Organ Tranpsplant Recipients: A Multicenter European Case Series (en)
|
| skos:prefLabel
| - Primary Cutaneous Posttransplant Lymphoproliferative Disorders in Solid Organ Tranpsplant Recipients: A Multicenter European Case Series
- Primary Cutaneous Posttransplant Lymphoproliferative Disorders in Solid Organ Tranpsplant Recipients: A Multicenter European Case Series (en)
|
| skos:notation
| - RIV/00669806:_____/13:10134351!RIV14-MZ0-00669806
|
| http://linked.open...avai/predkladatel
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00669806:_____/13:10134351
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - T cell; skin cancer; posttransplant lymphoproliferative disorder; posttransplant lymphoma; organ transplantation; immunosuppressant therapy; CD30 positive lymphoma; B cell (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - American Journal of Transplantation
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Cooper, S.
- del Marmol, V.
- Cetkovská, Petra
- Alaibac, M.
- Ali, I.
- Barete, S.
- Bavinck, J. N. Bouwes
- Durukan, E.
- Euvrard, S.
- Ferrándiz, C.
- Frances, C.
- Geusau, A.
- Gülec, A. T.
- Harwood, C. A.
- Holfbauer, G. F. L.
- Kanitakis, J.
- Kempf, W.
- Laffitte, E.
- Lebbé, C.
- Mork, C.
- Murphy, G. M.
- Proby, C. M.
- Seckin, D.
|
| http://linked.open...ain/vavai/riv/wos
| |
| issn
| |
| number of pages
| |
| http://bibframe.org/vocab/doi
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)